Tiago M.
- Country
- Portugal
- Department
- 3402: Serviço de Reumatologia
Research Overview
- Evaluation of Ianalumab Efficacy, Safety, and Tolerability in Diffuse Cutaneous Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Multicenter Study
- Evaluation of Efgartigimod PH20 SC Efficacy and Safety in Adult Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study
- Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Nipocalimab in Adults with Moderate to Severe Sjögren's Disease
Data & Insights
Has run more than one trial at 33 of 144 partner sites.
Specializations
Autoimmune Conditions
The investigator specializes in treating systemic sclerosis, with particular emphasis on its diffuse cutaneous variant (dcSSc). Their research focuses on innovative therapeutic approaches for managing this complex autoimmune condition.
- Skin Sclerosis Management
- Novel Biological Therapies
- Autoimmune Disease Treatment
Their expertise extends to evaluating advanced therapeutic agents targeting specific immune pathways in systemic sclerosis patients.
Clinical Assessment
The investigator employs comprehensive evaluation methods including the Revised Composite Response Index in Systemic Sclerosis for assessing treatment outcomes in clinical studies.
- Disease Progress Monitoring
- Treatment Response Assessment
- Clinical Outcome Measures
Their work involves evaluating both established and emerging therapeutic approaches for autoimmune conditions.
Therapeutic Innovation
The investigator explores cutting-edge treatments including subcutaneous immunomodulatory therapies and novel biological agents for systemic sclerosis treatment.
- Immunomodulation Studies
- Biological Therapy Development
- Treatment Safety Evaluation
Their research encompasses both safety and efficacy assessments of innovative therapeutic approaches.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.